0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Cytokines > TGF-beta 3 > TG3-H8218

Biotinylated Human Latent TGF-beta 3 / Latent TGFB3 Protein, Avitag™

This product is still under development. Please contact us if you have interest in this product. We will accelerate the development process accordingly and reserve this product for you as request.
  • Synonym
    TGFB3,ARVD,TGF-beta3
  • Source
    Biotinylated Human Latent TGFB3, Avitag (TG3-H8218) is expressed from human 293 cells (HEK293). It contains AA Ala 301 - Ser 412 (Accession # P10600-1).
    Predicted N-terminus: Ala 301
  • Molecular Characterization
    Online-Res(Ala 301 - Ser 412) P10600-1

    This protein carries an Avi tag at the C-terminus.

    The protein has a calculated MW of 14.4 kDa.

  • Biotinylation
    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
  • Endotoxin
  • Formulation

    Please contact us for detailed information.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • Background
    Transforming growth factor beta 3 ( TGFB3) is also known as TGF-β3, is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including regulates embryogenesis and cell differentiation and is required in various processes such as secondary palate development. TGF-beta 3 is similar with TGF-beta 1 and ­-beta 2, act as cellular switches to regulate immune function, cell proliferation, and epithelial­-mesenchymal transition. TGF-beta-3 is released from LAP by integrins: integrin-binding results in distortion of the LAP chain and subsequent release of the active TGF-beta-3. Once activated following release of LAP, TGF-beta-3 acts by binding to TGF-beta receptors (TGFBR1 and TGFBR2), which transduce signal.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $650.00

Price(USD) : $1800.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:1 Details
  • Latest Research Phase:Phase 1 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop